O
Omar Mamlouk
Researcher at University of Texas MD Anderson Cancer Center
Publications - 21
Citations - 632
Omar Mamlouk is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute kidney injury & Medicine. The author has an hindex of 4, co-authored 16 publications receiving 232 citations. Previous affiliations of Omar Mamlouk include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study
Frank B. Cortazar,Zoe A. Kibbelaar,Ilya G. Glezerman,Ala Abudayyeh,Omar Mamlouk,Shveta S. Motwani,Naoka Murakami,Sandra M. Herrmann,Sandhya Manohar,Anushree C. Shirali,Abhijat Kitchlu,Shayan Shirazian,Amer Assal,Anitha Vijayan,Amanda DeMauro Renaghan,David I. Ortiz-Melo,Sunil Rangarajan,A. Bilal Malik,Jonathan J. Hogan,Alex Dinh,Daniel Sanghoon Shin,Kristen A. Marrone,Zain Mithani,Douglas B. Johnson,Afrooz Hosseini,Deekchha Uprety,Shreyak Sharma,Shruti Gupta,Kerry L. Reynolds,Meghan E. Sise,David E. Leaf +30 more
TL;DR: Insight is identified into the risk factors, clinical features, histopathologic findings, and renal and overall outcomes in patients with immune checkpoint inhibitor-associated AKI.
Journal ArticleDOI
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Omar Mamlouk,Umut Selamet,Shana Machado,Maen Abdelrahim,William F Glass,Amanda Tchakarov,Lillian W. Gaber,Amit Lahoti,Biruh Workeneh,Sheldon Chen,Jamie S. Lin,Noha Abdel-Wahab,Noha Abdel-Wahab,Jean Tayar,Huifang Lu,Maria E. Suarez-Almazor,Nizar M. Tannir,Cassian Yee,Adi Diab,Ala Abudayyeh +19 more
TL;DR: Cases of biopsy proven acute tubulointerstitial nephritis and glomerulonephritis induced by immune checkpoint inhibitors are presented and it is demonstrated that ATIN is the most common pathological finding; however it can frequently co-occur with other glomerular pathologies, which may require immune suppressive therapy beyond corticosteroids.
Journal ArticleDOI
Acute kidney injury in patients treated with immune checkpoint inhibitors.
Shruti Gupta,Samuel A.P. Short,Meghan E. Sise,Jason Prosek,Sethu M. Madhavan,María José Soler,Marlies Ostermann,Sandra M. Herrmann,Ala Abudayyeh,Shuchi Anand,Ilya G. Glezerman,Shveta S. Motwani,Naoka Murakami,Rimda Wanchoo,David I. Ortiz-Melo,Arash Rashidi,Ben Sprangers,Ben Sprangers,Vikram Aggarwal,A. Bilal Malik,Sebastian Loew,Christopher A. Carlos,Wei-Ting Chang,Wei-Ting Chang,Pazit Beckerman,Zain Mithani,Chintan V. Shah,Amanda DeMauro Renaghan,Sophie De Seigneux,Luca Campedel,Abhijat Kitchlu,Daniel Sanghoon Shin,Sunil Rangarajan,Priya Deshpande,Gaia M. Coppock,Mark Eijgelsheim,Harish Seethapathy,Meghan Lee,Ian A. Strohbehn,Dwight H. Owen,Marium Husain,Clara García-Carro,Sheila Bermejo,Nuttha Lumlertgul,Nuttha Lumlertgul,Nina Seylanova,Nina Seylanova,Lucy Flanders,Busra Isik,Omar Mamlouk,Jamie S. Lin,Pablo Garcia,Aydin Kaghazchi,Yuriy Khanin,Sheru K Kansal,Els Wauters,Sunandana Chandra,Kai M. Schmidt-Ott,Kai M. Schmidt-Ott,Raymond K. Hsu,Maria C Tio,Suraj Sarvode Mothi,Harkarandeep Singh,Deborah Schrag,Kenar D. Jhaveri,Kerry L. Reynolds,Frank B. Cortazar,David E. Leaf +67 more
TL;DR: In this paper, a multivariable logistic regression model was used to identify predictors of ICPi-AKI and its recovery, and the effect of rechallenge versus no re-challenge on survival was estimated.
Journal ArticleDOI
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Omar Mamlouk,Jamie S. Lin,Maen Abdelrahim,Amanda Tchakarov,William F Glass,Umut Selamet,Maryam Buni,Noha Abdel-Wahab,Ala Abudayyeh +8 more
TL;DR: It is demonstrated that CPI can be associated with different types of renal vasculitis that are predominantly ANCA negative and manifest as severe acute kidney injury and treatment similar to treatment of primary seropositive ANCA-associated vasculopathy with corticosteroids and rituximab is well tolerated with favorable renal outcomes.
Journal ArticleDOI
Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis.
Jamie S. Lin,Omar Mamlouk,Umut Selamet,Amanda Tchakarov,William F. Glass,Rahul A. Sheth,Rachel M. Layman,Ramona Dadu,Noha Abdel-Wahab,Noha Abdel-Wahab,Maen Abdelrahim,Adi Diab,Cassian Yee,Ala Abudayyeh +13 more
TL;DR: In this paper, the authors report the first retrospective study examining the steroid-sparing potential of infliximab in achieving durable and complete renal recovery for patients with acute tubular interstitial nephritis (ATIN) induced acute kidney injury (AKI).